Hepatoprotection by Methylene Blue Against Doxorubicin Toxicity Through Coordinated Modulation of Oxidative Stress, ER Stress, and Apoptotic Pathways
Pharmaceuticals · 28.10.2025 · 18 (11) · 1625
DOI: 10.3390/ph18111625 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 28.10.2025. Verfasst von Enas S Gad und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, Kantara Branch, Ismailia 41636, Egypt. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Umm Al-Qura University, Saudi Arabia.
Abstract (Originalsprache)
Background and Objectives: Doxorubicin (DOX) is a potential chemotherapeutic whose clinical application is limited by hepatotoxicity mediated through apoptosis, endoplasmic reticulum (ER) stress, and oxidative stress (OS). This study aimed to assess the hepatoprotective impact of methylene blue (MB) against DOX-induced liver injury.
Methods
Forty rats were arbitrarily divided equally into four groups: control, DOX (15 mg/kg, i.p., single dose), MB (4 mg/kg, i.p., daily for 7 days), and DOX + MB (same regimen, MB initiated 1 h post DOX). Serum ALT, AST, and γ-GT were measured, along with hepatic TAC and HO-1. ELISA quantified PERK, GRP78, and CHOP. Immunohistochemistry assessed Caspase-3, p53, NF-κB, and Nrf2. Histopathological evaluation was performed using H&E staining.
Results
DOX administration significantly elevated ALT, AST, γ-GT, HO-1, PERK, GRP78, and CHOP while reducing TAC and Nrf2 expression. Strong Caspase-3, p53, and NF-κB immunoreactivity and severe histopathological damage were observed. MB treatment markedly reversed these changes, restoring antioxidant status, downregulating ER stress markers, preserving Nrf2 expression, and improving hepatic architecture.
Conclusions
MB exerts significant hepatoprotection against DOX-induced injury, likely via attenuation of OS, ER stress, apoptosis, and inflammation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sinai University, Kantara Branch, Ismailia 41636, Egypt.
- Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 13889, Saudi Arabia.
- Department of Pharmacology and Toxicology, College of Pharmacy, Umm Al-Qura University, P.O. Box 13578, Makkah 21955, Saudi Arabia.
- Department of Pharmacology, Egyptian Drug Authority (EDA)-Formerly NODCAR, Giza 12654, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Sohag University, Sohag 82511, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, October 6 University, Giza 12585, Egypt.
ORCID-Profile: Enas S Gad, Ahmed M Ashour, Shaimaa G Ibrahim, Mohamed H A Gadelmawla, Mona Mansour
Förderung
- Umm Al-Qura University, Saudi Arabia
Zitieren
APA
Gad, E. S., Ashour, A. M., Gad, A. M., Khames, A., Ibrahim, S. G., Gadelmawla, M. H. A., & Mansour, M. (2025). Hepatoprotection by Methylene Blue Against Doxorubicin Toxicity Through Coordinated Modulation of Oxidative Stress, ER Stress, and Apoptotic Pathways. Pharmaceuticals, 18(11), 1625. https://doi.org/10.3390/ph18111625
Vancouver
Gad ES, Ashour AM, Gad AM, Khames A, Ibrahim SG, Gadelmawla MHA, et al. Hepatoprotection by Methylene Blue Against Doxorubicin Toxicity Through Coordinated Modulation of Oxidative Stress, ER Stress, and Apoptotic Pathways. Pharmaceuticals. 2025;18(11):1625. doi:10.3390/ph18111625
BibTeX
@article{Gad2025,
author = {Gad, Enas S and Ashour, Ahmed M and Gad, Amany M and Khames, Ali and Ibrahim, Shaimaa G and Gadelmawla, Mohamed H A and Mansour, Mona},
title = {Hepatoprotection by Methylene Blue Against Doxorubicin Toxicity Through Coordinated Modulation of Oxidative Stress, ER Stress, and Apoptotic Pathways},
journal = {Pharmaceuticals},
year = {2025},
volume = {18},
number = {11},
pages = {1625},
doi = {10.3390/ph18111625}
}
EUVIMED